Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

FARAPULSE Pulsed Field Ablation (PFA) System is a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).

November 2, 2020

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on October 30, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 12 individuals hired by Sarepta in October 2020. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics notes employees received, in the aggregate, options to purchase 20,835 shares of Sarepta’s common stock, and in the aggregate, 8,385 restricted stock units (“RSUs”). The options have an exercise price of $135.91 per share, which is equal to the closing price of Sarepta’s common stock on October 30, 2020 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.

One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.

spot_img

DON'T MISS

Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles